Posted by Michael Wonder on 24 Aug 2020
FDA approves new Kyprolis (carfilzomib) combination regimen with Darzalex (daratumumab) and dexamethasone in both once- and twice-weekly dosing regimens
20 August 2020 - Approval based on the CANDOR and EQUULEUS studies in patients with relapsed/refractory multiple myeloma.
Amgen today announced the U.S. FDA has approved the expansion of the Kyprolis (carfilzomib) U.S. prescribing information to include its use in combination with Darzalex (daratumumab) plus dexamethasone in two dosing regimens — once weekly and twice weekly — for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.
